eCite Digital Repository

Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland

Citation

Frei, A and Palmer, AJ and Burnier, M and Hess, B, Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland, Praxis: Schweizerische Rundschau fuer Medizin , 95, (11) pp. 401-408. ISSN 1661-8157 (2006) [Refereed Article]

DOI: doi:10.1024/0369-8394.95.11.401

Abstract

The irbesartan in Diabetic Nephropathy Trial (IDNT) demonstrated that treatment of patients with type 2 diabetes, hypertension and nephropathy with irbesartan resulted in a 20% relative reduction of the composite endpoint of doubling serum creatinine, end-stage renal disease or death as compared with amlodipine and placebo (antihypertensive standard therapy). The objective of this study was to investigate the long-term health economic consequences of this treatment strategy in a Swiss health care setting. This analysis used a Markov model to simulate the progression of nephropathy, life-years and treatment costs over ten years for each of the three treatment options. In additon, sensitivity analyses were performed. Treatment with irbesartan will save CHF 22 681/patient as compared with amlodipine and CHF 13 847 as compared with standard therapy. © 2006 by Verlag Hans Huber, Hogrefe AG.

Item Details

Item Type:Refereed Article
Research Division:Economics
Research Group:Applied Economics
Research Field:Health Economics
Objective Division:Health
Objective Group:Health and Support Services
Objective Field:Health Policy Economic Outcomes
ID Code:74670
Year Published:2006
Deposited By:Research Division
Deposited On:2011-12-09
Last Modified:2011-12-13
Downloads:0

Repository Staff Only: item control page